Research cutoff: September 14, 2026. This guide addresses investment research, not medical treatment decisions. The examples are hypothetical and use USD.
To evaluate a biotech stock, separate the clinical evidence, the regulatory decision, the commercial opportunity and the cash needed to reach the next milestone. A promising trial headline is not an approval, and an approval alone does not establish an attractive investment.
Start with what the study actually tested
The FDA’s clinical-research overview describes the different purposes of clinical study phases. Early studies typically emphasize safety and dosing; later studies investigate effectiveness and continue assessing safety. The phase label alone does not tell you that a product will succeed. Look at the actual study design and its results.
For an investor’s research note, record the studied population, comparator, main endpoint, follow-up period and material safety findings. Ask whether the headline concerns the prespecified main analysis or only a subgroup. A change in a laboratory measure is not automatically the same as an improvement in how patients feel, function or survive. Do not make a treatment conclusion from an investment article.
Keep the development steps separate
The FDA’s drug-development process distinguishes clinical research, regulatory review and post-market monitoring. The agency’s review explanation describes how an application is assessed. A company announcing that it submitted an application has not announced that the FDA approved it.
On small screens, swipe the table horizontally. Keyboard users can focus the table region and use the arrow keys.
| Headline | What to verify | What remains unanswered |
|---|---|---|
| Trial met an endpoint | Study design, main analysis, effect size and safety data | Whether the total evidence supports the intended use |
| Application submitted | What was submitted and the regulator’s documented status | Acceptance, review outcome and any restrictions |
| Product approved | Official label, population and conditions of use | Commercial adoption, costs and shareholder returns |
| Funded through a milestone | Cash definition, spending assumptions and obligations | Whether delays or higher costs create another financing need |
Cash runway: a useful estimate with limits
Read the latest financial statements and subsequent financing announcements, not just a slide saying the company is well funded. The SEC’s 10-K and 10-Q guide explains where business risks, financial statements and management’s discussion fit in the reporting package. Check liquidity and spending disclosures together.
Suppose a fictional company has $240 million of available cash and uses $30 million each quarter. Simple runway is $240 million ÷ $30 million = eight quarters. If spending increases to $40 million quarterly, runway falls to six quarters. Neither result includes a new financing, a change in spending, restricted cash or other commitments unless you explicitly add them.
Now place the expected milestone on that timeline. A trial readout in seven quarters would fall within the first scenario but outside the second. This is a reason to investigate funding assumptions, not a prediction of insolvency. Trial delays, manufacturing investment and contractual payments can all change the cash schedule. A historical burn rate is a starting point, not a promise.
Calculate the ownership effect of new shares
Imagine you own one million shares in a company with 100 million shares outstanding: your ownership is 1%. If it issues 25 million additional shares and you buy none, you own one million out of 125 million, or 0.8%. Your percentage interest falls by 20%, even though the new issuance equals 25% of the old share count.
That calculation does not mean the stock must lose 20% of its value. The business receives financing, and the price and terms of the issue matter. Evaluate the cash raised, fees, warrants, convertibles and the progress the funds can finance. A simplified share-count example cannot determine fair value by itself.
Good science and a good investment are separate tests
After assessing evidence and financing, examine the commercial assumptions. Identify the intended market, competing treatments, reimbursement uncertainties, manufacturing capacity and the company’s share of any partnered economics. Avoid treating the entire population with a condition as an automatic paying customer base. Do not multiply a large population by a hypothetical price and call the result a revenue forecast.
Our practical research sheet has four columns: verified fact, source and date, unresolved question, and the next evidence that could answer it. Keep approval odds blank unless you have a defensible model and clearly stated limitations. An exact percentage copied from a generic historical average can give a misleading impression of knowledge about one specific program.
Frequently asked questions
Does a late-stage trial guarantee approval?
No. The complete evidence and regulatory review still matter. Investment research cannot substitute for that assessment.
Does more cash always remove financing risk?
No. Available cash must be compared with spending, obligations and the timing of future work.
Continue the financial research
Review EPS and share-count mechanics and the limits of smooth compounding assumptions. Biotech outcomes can be discontinuous; a steady annual growth assumption can hide the risk of a single major event.
LiveTodayStock editorial research. Educational information, not personalized investment advice. Investment values can fall. No return, price target or future result is guaranteed.